Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta‐analysis

Topical and systemic prophylactic measures, which are administered before the development of epidermal growth factor receptor (EGFR)‐related acneiform rash, are appropriate interventions to mitigate the intensity of skin toxicity. We have performed a systematic review and meta‐analysis to evaluate whether prophylactic antibiotics may reduce the occurrence and severity of anti‐EGFR drug‐related skin rashes. A systematic review was performed by searching Medline, Scopus, Embase, CINAHL, LILACS, Web of Science and the Cochrane Library from inception until March 2016 for publications regarding the pre‐emptive role of antibiotics for EGFR‐induced skin rashes. Fixed‐ or random‐effects meta‐analyses, according to heterogeneity, were used to summarize odds ratios of skin toxicity with antibiotic use. Of the 827 citations found in the search, 13 studies comprising 1073 patients were included in the analysis. In 12 studies, patients in the prophylactic antibiotic arms had a lower risk of developing a skin rash (odds ratio 0·53, 95% confidence interval 0·39–0·72, P < 0·01) than patients without antibiotic prophylaxis. In particular, moderate‐to‐severe toxicities (grades 2–4) were reduced by nearly two‐thirds (odds ratio 0·36, 95% confidence interval 0·22–0·60, P < 0·01) in 13 studies. This translated to a 26% absolute difference of high‐grade skin rash compared with the control arms (from 50% to 24%). The results of this meta‐analysis show that the risk of skin rash after treatment with anti‐EGFR agents for solid tumours was significantly lower in patients taking prophylaxis with antibiotics than in those who were not. Therefore, taking pre‐emptive tetracyclines for several weeks at the start of anti‐EGFR treatment can significantly reduce the incidence and severity of cutaneous acneiform rash.

[1]  V. Ho,et al.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Robert,et al.  Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. , 2016, Journal of the American Academy of Dermatology.

[3]  H. Kennecke,et al.  Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer , 2016, Supportive Care in Cancer.

[4]  Kazuhiro Yoshida,et al.  Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. , 2015, Anticancer research.

[5]  M. Benasso,et al.  Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. , 2015, Critical reviews in oncology/hematology.

[6]  O. Arrieta,et al.  Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. , 2015, Lung cancer.

[7]  M. Lacouture,et al.  Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics. , 2015 .

[8]  Hideaki Takahashi,et al.  Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study , 2015, American Journal of Clinical Dermatology.

[9]  K. Hatanaka,et al.  Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. , 2015, Future oncology.

[10]  F. de Marinis,et al.  management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. , 2014, Clinical lung cancer.

[11]  C. Sonetto,et al.  Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. , 2014, Clinical colorectal cancer.

[12]  J. Fischer,et al.  Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.

[13]  P. Galle,et al.  Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective , 2013, Journal of Cancer Research and Clinical Oncology.

[14]  H. Tomková,et al.  Phytomenadione pre‐treatment in EGFR inhibitor‐induced folliculitis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  S. Barni,et al.  The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials , 2013, Targeted Oncology.

[16]  S. Barni,et al.  Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. , 2012, Lung cancer.

[17]  O. Chosidow,et al.  Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature , 2012, The British journal of dermatology.

[18]  M. Ychou,et al.  Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. , 2012, The oncologist.

[19]  A. Rademaker,et al.  Higher severity grade of erlotinib‐induced rash is associated with lower skin phototype , 2011, Clinical and experimental dermatology.

[20]  P. Novotny,et al.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB) , 2011, Supportive Care in Cancer.

[21]  M. Lacouture,et al.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities , 2011, Supportive Care in Cancer.

[22]  E. Maiello,et al.  Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. , 2011, The oncologist.

[23]  M. Lacouture,et al.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Sargent,et al.  Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 , 2008, Oncology.

[25]  A. Halpern,et al.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[27]  G. Girolomoni,et al.  Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. , 2003, The American journal of pathology.

[28]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[29]  Jong Hoon Kim,et al.  Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. , 2013, European journal of dermatology : EJD.

[30]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[31]  B. Thiers.  Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-induced Skin Rashes: Results of a Placebo-controlled Trial From the North Central Cancer Treatment Group (N03CB) , 2009 .

[32]  K. Ang,et al.  Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.